CLRB Cellectar Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLRB

Price (delayed)

$3.42

Market cap

$110.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.11

Enterprise value

$101.32M

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. ...

Highlights
The company's EPS rose by 23% YoY and by 4.3% QoQ
The company's debt fell by 8% YoY and by 2.8% QoQ
The equity has plunged by 109% YoY but it has soared by 90% from the previous quarter
CLRB's quick ratio has plunged by 79% YoY and by 36% from the previous quarter
Cellectar Biosciences's net income has decreased by 33% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cellectar.com
Peers: VBIV GLYC

Key stats

What are the main financial stats of CLRB
Market
Shares outstanding
32.26M
Market cap
$110.33M
Enterprise value
$101.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$38.04M
EBITDA
-$37.79M
Free cash flow
-$33.24M
Per share
EPS
-$3.11
Free cash flow per share
-$2.72
Book value per share
-$0.11
Revenue per share
$0
TBVPS
$0.99
Balance sheet
Total assets
$12.08M
Total liabilities
$13.43M
Debt
$552,982
Equity
-$1.36M
Working capital
-$2.48M
Liquidity
Debt to equity
-0.41
Current ratio
0.81
Quick ratio
0.74
Net debt/EBITDA
0.24
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-276.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLRB stock price

How has the Cellectar Biosciences stock price performed over time
Intraday
2.4%
1 week
12.87%
1 month
-14.07%
1 year
126.49%
YTD
23.47%
QTD
-14.07%

Financial performance

How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.96M
Net income
-$37.98M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's operating income has decreased by 35% YoY and by 15% from the previous quarter
Cellectar Biosciences's net income has decreased by 33% YoY

Growth

What is Cellectar Biosciences's growth rate over time

Valuation

What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 23% YoY and by 4.3% QoQ
The equity has plunged by 109% YoY but it has soared by 90% from the previous quarter

Efficiency

How efficient is Cellectar Biosciences business performance
The company's return on assets has shrunk by 139% YoY and by 18% QoQ

Dividends

What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLRB.

Financial health

How did Cellectar Biosciences financials performed over time
The total assets is 10% less than the total liabilities
The total liabilities has soared by 121% YoY but it has contracted by 21% from the previous quarter
CLRB's quick ratio has plunged by 79% YoY and by 36% from the previous quarter
The company's debt is 141% higher than its equity
The equity has plunged by 109% YoY but it has soared by 90% from the previous quarter
The company's debt fell by 8% YoY and by 2.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.